← ANALYST RATINGS · TIPRANKS
TriSalus Life Sciences (TLSI): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $10.00, the highest $12.00, the lowest $7.00. The average is +175.5% from the last price of $3.63.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $4.00 → $3.50−12.5% | Hold | −3.6% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $4.00 → $3.50−12.5% | Hold | −3.6% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $4.00 → $3.50−12.5% | Hold | −3.6% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $4.00 → $3.50−12.5% | Hold | −3.6% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $3.50−12.5% | Hold | −3.6% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $4.50 → $3.50−22.2% | Hold | −3.6% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $12.00 | Buy | +230.6% | Reiterated | 01.10.26on TipRanks 06:35 | −3.9%next day +3.4% · 5 days −1.8% | ↗ |
| Frank Takkinen★★★★★★★★★★#11823 · hits 38% · avg −3.6% | Lake Street | $8.00 | Buy | +120.4% | Reiterated | 23.09.26on TipRanks 09:10 | +2.1%next day −7.7% · 5 days −13.1% | ↗ |
| William Plovanic★★★★★★★★★★#5377 · hits 43% · avg +1.3% | Canaccord Genuity | $7.00 | Buy | +92.8% | Reiterated | 23.09.26on TipRanks 07:15 | +2.1%next day −7.7% · 5 days −13.1% | ↗ |
| Jason McCarthy★★★★★★★★★★#12398 · hits 30% · avg −13.6% | Maxim Group | $10.00 → $14.00+40.0% | Buy | +285.7% | Assigned | 10.08.26on TipRanks Aug 11 08:12 | −0.5%next day +3.2% · 5 days −5.5% | ↗ |
| Justin Walsh★★★★★★★★★★#640 · hits 39% · avg +20.6% | JonesTrading | $11.00 | Buy | +203.0% | Reiterated | 10.08.26on TipRanks 12:10 | −0.5%next day +3.2% · 5 days −5.5% | ↗ |
| Carl Byrnes★★★★★★★★★★#11765 · hits 37% · avg −4.0% | Northland Securities | $12.50 → $8.00−36.0% | Buy | +120.4% | Assigned | 23.03.26on TipRanks 09:20 | −1.3%next day −0.4% · 5 days −1.8% | ↗ |
| Suraj Kalia★★★★★★★★★★#1646 · hits 50% · avg +6.8% | Oppenheimer | $10.00 | Buy | +175.5% | Reiterated | 14.11.25on TipRanks 18:40 | −0.8%next day +3.5% · 5 days +23.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering TriSalus Life Sciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $10.40 at a price of $4.31 (+141.3%); now: $10.40 at $3.63 (+186.5%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 3 | 2 | 3 | 4 |
| Buy | 0 | 0 | 0 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 12.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.13 (from $-0.15 to $-0.09). Last quarter: $-0.16.
Sales
Next quarter’s sales estimate — $14M (from $13M to $14M). Last quarter: $11M.
Best top-analyst consensus in the sector · Healthcare
About TriSalus Life Sciences
- CEO: Mary T. Szela
- Employees: 102
- 6272 West 91st Avenue, Westminster, CO, 80031, US
- trisaluslifesci.com
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
Data from the stock’s TipRanks forecast page, read 117 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗